본문 바로가기
KERD
논문KCI 등재

Current Understanding of Mineral and Bone Disorders of Chronic Kidney Disease and the Scientific Grounds on the Use of Exogenous Parathyroid Hormone in Its Management

Michael Pazianas|Paul Dennis Miller
대한골대사학회 (The Korean Society of Bone Metabolism)|2020.02|대한골대사학회지 (Journal of Bone Metabolism)|제27권 제1호|pp. 1-13

2

조회

0

다운로드

0

인용

0

참고문헌

주제분류정형외과학

초록

Chronic Kidney disease (CKD) disturbs mineral homeostasis leading to mineral and bone disorders (MBD). Serum calcium and phosphate (Pi) remain normal until the late stages of CKD at the expense of elevate fibroblast growth factor-23 (FGF-23), a phosphaturic hormone, followed by reduced 1,25-dihydroxy-vitamin D (1,25[OH]2D) and finally elevated parathyroid hormone (PTH). Pi retention is thought to be the initial cause of CKD-MBD. The management of MBD is a huge clinical challenge because the effectiveness of current therapeutic regimens to prevent and treat MBD is limited. An intermittent regimen of PTH, when administered at the early stages of CKD, through its phosphaturic action, could prevent FGF-23 increases, the drop of 1,25(OH)2D, and the development of renal osteodystrophy, including secondary hyperparathyroidism (HPT) and its catabolic effects on the skeleton. Even in more advanced stages of CKD that have not progressed to tertiary HPT, could be beneficial. Therapeutic effects could be achieved in vascular calcification as well. Limited experimental/clinical data support the effectiveness of PTH in CKD-MBD. Its safety, has been established only when it is used for the treatment of osteoporosis, including patients with CKD. The proposed intermittent PTH administration is biologically plausible but its effectiveness and safety has to be critically assessed in long term prospective studies in patients with CKD-MBD

Abstract

Chronic Kidney disease (CKD) disturbs mineral homeostasis leading to mineral and bone disorders (MBD). Serum calcium and phosphate (Pi) remain normal until the late stages of CKD at the expense of elevate fibroblast growth factor-23 (FGF-23), a phosphaturic hormone, followed by reduced 1,25-dihydroxy-vitamin D (1,25[OH]2D) and finally elevated parathyroid hormone (PTH). Pi retention is thought to be the initial cause of CKD-MBD. The management of MBD is a huge clinical challenge because the effectiveness of current therapeutic regimens to prevent and treat MBD is limited. An intermittent regimen of PTH, when administered at the early stages of CKD, through its phosphaturic action, could prevent FGF-23 increases, the drop of 1,25(OH)2D, and the development of renal osteodystrophy, including secondary hyperparathyroidism (HPT) and its catabolic effects on the skeleton. Even in more advanced stages of CKD that have not progressed to tertiary HPT, could be beneficial. Therapeutic effects could be achieved in vascular calcification as well. Limited experimental/clinical data support the effectiveness of PTH in CKD-MBD. Its safety, has been established only when it is used for the treatment of osteoporosis, including patients with CKD. The proposed intermittent PTH administration is biologically plausible but its effectiveness and safety has to be critically assessed in long term prospective studies in patients with CKD-MBD

참고문헌 (70)

  1. Yanagawa N, "Clinical disorders of fluid and electrolyte metabolism", pp.307~372 (1994), MacGraw Hill
  2. "Regulation of calcium and phosphate balance" (2018)[URL]
  3. Jacquillet G, "Physiological regulation of phosphate by vitamin D, parathyroid hormone (PTH) and phosphate (Pi)", Pflugers Arch, 471, pp.83~98 (2019)
  4. Brown EM, "Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue", J Clin Endocrinol Metab, 56, pp.572~581 (1983)
  5. Biber J, "Renal handling of phosphate and sulfate", Compr Physiol, 4, pp.771~792 (2014)
  6. Bikle D, "Primer on the metabolic bone diseases and disorders of mineral metabolism" (2013), American Society for Bone and Mineral Research
  7. Inoue Y, "Role of the vitamin D receptor in FGF23 action on phosphate metabolism", Biochem J, 390, pp.325~331 (2005)
  8. Martin A, "Regulation and function of the FGF23", klotho endocrine pathways, 2012, pp.92, 131~155
  9. Bricker NS, "On the pathogenesis of the uremic state. An exposition of the "trade-off hypothesis"", N Engl J Med, 286, pp.1093~1099 (1972)
  10. Moe S, "Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)", Kidney Int, 69, pp.1945~1953 (2006)
  11. "Bone biopsy and the diagnosis of renal osteodystrophy" (2017)[URL]
  12. Parfitt AM, "Renal bone disease : a new conceptual framework for the interpretation of bone histomorphometry", Curr Opin Nephrol Hypertens, 12, pp.387~403 (2003)
  13. Goodman WG, "Development and progression of secondary hyperparathyroidism in chronic kidney disease : lessons from molecular genetics", Kidney Int, 74, pp.276~288 (2008)
  14. Houillier P, "What serum calcium can tell us and what it can't", Nephrol Dial Transplant, 21, pp.29~32 (2006)
  15. Grams ME, "Lifetime incidence of CKD stages 3-5 in the United States", Am J Kidney Dis, 62, pp.245~252 (2013)
  16. "2017 USRDS Annual Data Report: Chapter 1. CKD in the general population" (2017)[URL]
  17. "Chronic kidney disease prevalence model" (2014)[URL]
  18. Malluche HH, "Bone histology in incipient and advanced renal failure", Kidney Int, 9, pp.355~362 (1976)
  19. Reichel H, "Calcium metabolism in early chronic renal failure : implications for the pathogenesis of hyperparathyroidism", Nephrol Dial Transplant, 6, pp.162~169 (1991)
  20. Levin A, "Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease", Kidney Int, 71, pp.31~38 (2007)
  21. Isakova T, "FGF23 or PTH : which comes first in CKD", Kidney Int, 78, pp.947~949 (2010)
  22. Hasegawa H, "Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease", Kidney Int, 78, pp.975~980 (2010)
  23. Shigematsu T, "Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency", Am J Kidney Dis, 44, pp.250~256 (2004)
  24. Gutierrez O, "Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease", J Am Soc Nephrol, 16, pp.2205~2215 (2005)
  25. Vervloet MG, "The role of phosphate in kidney disease", Nat Rev Nephrol, 13, pp.27~38 (2017)
  26. De Broe ME., "Phosphate: despite advances in research, the benefits to patients remain limited", Kidney Int, 75, pp.880~881 (2009)
  27. Marcuccilli M, "Phosphate binders and targets over decades : Do we have it right now", Semin Dial, 30, pp.134~141 (2017)
  28. Isakova T, "Rationale and approaches to phosphate and fibroblast growth factor 23 reduction in CKD", J Am Soc Nephrol, 26, pp.2328~2339 (2015)
  29. Ruospo M, "Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder(CKD-MBD)", Cochrane Database Syst Rev, 8, pp.Cd006023~ (2018)
  30. Ketteler M, "Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder(CKD-MBD)Guideline Update : what’s changed and why it matters", Kidney Int, 92, pp.26~36 (2017)
  31. Memmos DE, "Talner LB, et al. Double-blind trial of oral 1,25-dihydroxy vitamin D3 versus placebo in asymptomatic hyperparathyroidism in patients receiving maintenance haemodialysis", Br Med J(Clin Res Ed), 282, pp.1919~1924 (1981)
  32. Toussaint ND, "Do the benefits of using calcitriol and other vitamin D receptor activators in patients with chronic kidney disease outweigh the harms?", Nephrology (Carlton), 22(Suppl 2), pp.51~56 (2017)
  33. Nemeth EF, "Calcimimetic and calcilytic drugs: Feats, flops, and futures", Calcif Tissue Int, 98, pp.341~358 (2016)
  34. Vervloet M, "Renal and extrarenal effects of fibroblast growth factor 23", Nat Rev Nephrol, 15, pp.109~120 (2019)
  35. Shalhoub V, "FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality", J Clin Invest, 122, pp.2543~2553 (2012)
  36. Scialla JJ, "Fibroblast growth factor-23 and cardiovascular events in CKD", J Am Soc Nephrol, 25, pp.349~360 (2014)
  37. Faul C, "FGF23 induces left ventricular hypertrophy", J Clin Invest, 121, pp.4393~4408 (2011)
  38. Gutiérrez OM, "Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease", Circulation, 119, pp.2545~2552 (2009)
  39. Seeherunvong W, "Fibroblast growth factor 23 and left ventricular hypertrophy in children on dialysis", Pediatr Nephrol, 27, pp.2129~2136 (2012)
  40. Andrukhova O, "FGF23 regulates renal sodium handling and blood pressure", EMBO Mol Med, 6, pp.744~759 (2014)
  41. Marthi A, "Fibroblast growth factor-23 and risks of cardiovascular and noncardiovascular diseases : A meta-analysis", J Am Soc Nephrol, 29, pp.2015~2027 (2018)
  42. Kovesdy CP, "FGF23 from bench to bedside", Am J Physiol Renal Physiol, 310, pp.F1168~F1174 (2016)
  43. Adler AJ, "Effect of inorganic phosphate on serum ionized calcium concentration in vitro : a reassessment of the"trade-off hypothesis"", Kidney Int, 28, pp.932~935 (1985)
  44. Mace ML, "Fibroblast growth factor (FGF) 23 regulates the plasma levels of parathyroid hormone In vivo through the FGF receptor in normocalcemia, but not in hypocalcemia", Calcif Tissue Int, 102, pp.85~92 (2018)
  45. Massry SG, "Skeletal resistance to parathyroid hormone in renal failure. Studies in 105 human subjects", Ann Intern Med, 78, pp.357~364 (1973)
  46. Scialla JJ, "Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease", Nat Rev Nephrol, 10, pp.268~278 (2014)
  47. Fang Y, "Early chronic kidney disease-mineral bone disorder stimulates vascular calcification", Kidney Int, 85, pp.142~150 (2014)
  48. Cozzolino M, "Cardiovascular disease in dialysis patients", Nephrol Dial Transplant, 33, pp.iii28~iii34 (2018)
  49. Herzog CA, "Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)", Kidney Int, 80, pp.572~586 (2011)
  50. "2018 USRDS Annual Data Report: Chapter 4. Cardiovascular disease in patients with CKD" (2018)[URL]
  51. Goodman WG, "Vascular calcification in chronic kidney disease", Am J Kidney Dis, 43, pp.572~579 (2004)
  52. Kandula P, "Vitamin D supplementation in chronic kidney disease : a systematic review and meta-analysis of observational studies and randomized controlled trials", Clin J Am Soc Nephrol, 6, pp.50~62 (2011)
  53. Kuro OM, "A phosphate-centric paradigm for pathophysiology and therapy of chronic kidney disease", Kidney Int Suppl(2011), 3, pp.420~426 (2013)
  54. Alshayeb HM, "Primer on the metabolic bone diseases and disorders of mineral metabolism", pp.640~650 (2013), American Society for Bone and Mineral Research
  55. Oliveira RB, "Early control of PTH and FGF23 in normophosphatemic CKD patients : a new target in CKD-MBD therapy", Clin J Am Soc Nephrol, 5, pp.286~291 (2010)
  56. Pavik I, "Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5 : a sequence suggested from a cross-sectional study", Nephrol Dial Transplant, 28, pp.352~359 (2013)
  57. Palcu P, "Teriparatide and bone turnover and formation in a hemodialysis patient with low-turnover bone disease : a case report", Am J Kidney Dis, 65, pp.933~936 (2015)
  58. Tabacco G, "Osteoanabolic and dual action drugs", Br J Clin Pharmacol, 85, pp.1084~1094 (2019)
  59. Macdonald HM, "Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis", Osteoporos Int, 22, pp.357~362 (2011)
  60. Doyle N, "Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption", Osteoporos Int, 29, pp.685~697 (2018)
  61. Besschetnova T, "Abaloparatide improves cortical geometry and trabecular microarchitecture and increases vertebral and femoral neck strength in a rat model of male osteoporosis", Bone, 124, pp.148~157 (2019)
  62. Watts NB, "Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis", Osteoporos Int, 30, pp.1187~1194 (2019)
  63. Hattersley G, "Binding selectivity of abaloparatide for PTH-Type-1-receptor conformations and effects on downstream signaling", Endocrinology, 157, pp.141~149 (2016)
  64. Drüeke TB, "Changing bone patterns with progression of chronic kidney disease", Kidney Int, 89, pp.289~302 (2016)
  65. Junya Yamamoto, "Impact of Weekly Teriparatide on the Bone and Mineral Metabolism in Hemodialysis Patients With Relatively Low Serum Parathyroid Hormone: A Pilot Study", Therapeutic Apheresis and Dialysis, 24(2), pp.146~153 (2019), Wiley[DOI]
  66. Sebastian EM, "Differential effects of intermittent PTH(1-34)and PTH(7-34)on bone microarchitecture and aortic calcification in experimental renal failure", Bone, 43, pp.1022~1030 (2008)
  67. Ota M, "Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia", Osteoporos Int, 28, pp.1481~1490 (2017)
  68. Miller PD, "Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment", Osteoporos Int, 18, pp.59~68 (2007)
  69. Nishikawa A, "Safety and effectiveness of daily teriparatide for osteoporosis in patients with severe stages of chronic kidney disease : post hoc analysis of a postmarketing observational study", Clin Interv Aging, 11, pp.1653~1659 (2016)
  70. Nordholm A, "A potential kidney-bone axis involved in the rapid minute-to-minute regulation of plasma Ca2+", BMC Nephrol, 16, pp.29~ (2015)

관련 논문AI추천

Clinical Utility of Bone Turnover Markers in Chronic Kidney DiseasePraopilad Srisuwarn, Richard Eastell, Syazrah Salam대한골대사학회 · 대한골대사학회지2024 · 제31권 제4호Comparison of Intact PTH and Bio-Intact PTH Assays Among Non-Dialysis Dependent Chronic Kidney Disease PatientsEliezer Golan, Sydney Benchetrit, Tali Zitman-Gal, Yael Einbinder대한진단검사의학회 · Annals of Laboratory Medicine2017 · 제37권 제5호Diagnosis and Management of Chronic Kidney Disease- Mineral Bone Disease in Children서진순대한소아신장학회 · Childhood Kidney Diseases2020 · 제24권 제1호Linkage of Fibroblast Growth Factor 23 and Phosphate in Serum: Phosphate and Fibroblast Growth Factor 23 Reduction by Increasing Dose of SevelamerAmir Ghorbanihaghjo, Amir Mansour Vatankhah, Davoud Sanajou, Hassan Argani, Mehran Mesgari Abbasi, Nadereh Rashtchizadeh, Nasrin Bargahi, Zahra Golmohamadi대한골대사학회 · 대한골대사학회지2018 · 제25권 제3호Chronic Kidney Disease-mineral Bone Disorder and Active Vitamin D Analogs for Treating Severe Hyperparathyroidism in Children Receiving Chronic Peritoneal Dialysis강은구, 박영서, 이주훈대한소아신장학회 · Childhood Kidney Diseases2014 · 제18권 제2호Sevelamer 인결합제와 투석환자의 Chronic Kidney Disease-Mineral Bone Disorder 관리신승우, 신혜연한국임상약학회 · 한국임상약학회지2016 · 제26권 제2호

이 간행물의 다른 논문 (7건)

Effect of Osteoporosis Medication on Fracture Healing: An Evidence Based Review신원철, 신영호, 김지완pp. 15-26Risk of Osteoporotic Fracture in Patients with Breast Cancer: Meta-AnalysisSeok Min Lim, 이영균, Jung-Wee Park, Kyung-Hoi Koo, 유준일, Yong-Chan Ha, Seeyoun Lee, Seokhyung Won, Jiung Yeom, Jin Woo Impp. 27-34Characteristics of Appendicular Tissue Components in Patients with Rheumatoid Arthritis윤병호, 구본산pp. 35-42Reference Intervals for Bone Turnover Markers in Korean Healthy WomenJeong-Ran Cho, Min-Young Chung, 정동진, 조동혁, 정진욱pp. 43-52Inhibitory Effect of Rosae Multiflorae Fructus Extracts on the Receptor Activator of NF-κB Ligand-Induced Osteoclastogenesis through Modulation of P38- and Ca2+-Mediated Nuclear Factor of Activated T-Cells Cytoplasmic 1 ExpressionKeun Ha Park, 구동련, Min Seuk Kim, 이승훈pp. 53-63
원문 보기